Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoxin Wu

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
AIDS (London, England)|September 29, 2021
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversalJames H McMahon, Vanessa A Evans, Jillian S Y Lau, et al.
The Journal of Biological Chemistry|March 2, 2005
Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeuticsAmy S Espeseth, Min Xu, Qian Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2021
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral TherapyEmmanouil Papasavvas, Livio Azzoni, Brian N Ross, et al.
The Journal of Clinical Investigation|March 1, 2022
Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapyJustin Harper, Susan P Ribeiro, Chi Ngai Chan, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
The Journal of Clinical Investigation|September 21, 2023
Initial productive and latent HIV infections originate in vivo by infection of resting T cellsStephen W Wietgrefe, Jodi Anderson, Lijie Duan, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
Nature Immunology|January 17, 2025
Author Correction: Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruptionSusan Pereira Ribeiro, Zachary Strongin, Hugo Soudeyns, et al.
Nature Immunology|September 12, 2024
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruptionSusan Pereira Ribeiro, Zachary Strongin, Hugo Soudeyns, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
AIDS (London, England)|September 29, 2021
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversalJames H McMahon, Vanessa A Evans, Jillian S Y Lau, et al.
The Journal of Biological Chemistry|March 2, 2005
Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeuticsAmy S Espeseth, Min Xu, Qian Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2021
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral TherapyEmmanouil Papasavvas, Livio Azzoni, Brian N Ross, et al.
The Journal of Clinical Investigation|March 1, 2022
Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapyJustin Harper, Susan P Ribeiro, Chi Ngai Chan, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
The Journal of Clinical Investigation|September 21, 2023
Initial productive and latent HIV infections originate in vivo by infection of resting T cellsStephen W Wietgrefe, Jodi Anderson, Lijie Duan, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
Nature Immunology|January 17, 2025
Author Correction: Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruptionSusan Pereira Ribeiro, Zachary Strongin, Hugo Soudeyns, et al.
Nature Immunology|September 12, 2024
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruptionSusan Pereira Ribeiro, Zachary Strongin, Hugo Soudeyns, et al.
Pageof 8